European Primary Care Cardiovascular Society

All three end points show benefit with another SLGT2 inhibitor in HFrEF

3' education - Sep. 16, 2020 - Milton Packer, MD

SGLT2i provides nephroprotective effects in CKD patients

3' education - Sep. 16, 2020 - Prof. Hiddo Heerspink, PhD

Improved outcomes with early rhythm control in AF

3' education - Sep. 16, 2020 - Prof. Paulus Kirchhof, MD

Proportion of unrecognized MI greater in women

5' education - Aug. 19, 2020 - Yldau van der Ende, MD, PhD

Recovered COVID-19 patients and cardiac abnormalities

3' education - Aug. 19, 2020 - Prof. Rudolf de Boer, MD, PhD

How to detect familial hypercholesterolemia

10' education - July 29, 2020 - Rens Reeskamp, MD

Screening for familial hypercholesterolemia - why and how?

10' education - July 27, 2020 - Prof. Kees Hovingh, MD, PhD

Need for early detection of familial hypercholesterolemia

10' education - July 22, 2020 - Bert Wiegman, MD, PhD

More out-of-hospital cardiac arrest during COVID-19 outbreak in Lombardy, Italy

3' education - June 18, 2020 - Enrico Baldi, MD

Screening for AF, HF and CAD in primary care

5' education - June 16, 2020 - Victor Zwartkruis
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - May 14, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

COVID-19, ACE2 and RAASi - a clinical perspective

10' education - May 14, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

What are the implications for practice? - A discussion on COVID-19, ACE2 and RAASi

10' education - May 14, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

A call to collect data on CV variables in patients with COVID-19

3' education - Apr. 14, 2020 - Prof. Folkert Asselbergs, MD, PhD

Rate of smoking cessation higher with e-cigarettes compared to counseling

3' education - Apr. 13, 2020 - Prof. Mark Eisenberg, MD - ACC 2020

Mechanistic evidence of CV benefit observed with icosapent ethyl

3' education - Apr. 12, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

A little closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 11, 2020 - Dirk Blom, PhD

sGC stimulator has added value in worsening HFrEF patients

3' education - Apr. 10, 2020 - Prof. Paul Armstrong, MD - ACC 2020

Reliable results with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Apr. 9, 2020 - Prof. Deepak Bhatt, MD

Significant reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 8, 2020 - Prof. Frederick Raal, PhD - ACC 2020

All three end points show benefit with another SLGT2 inhibitor in HFrEF

3' education - Sep. 16, 2020 - Milton Packer, MD
Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.

ESC 2020 Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.

SGLT2i provides nephroprotective effects in CKD patients

3' education - Sep. 16, 2020 - Prof. Hiddo Heerspink, PhD
After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.

ESC 2020 After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.

Improved outcomes with early rhythm control in AF

3' education - Sep. 16, 2020 - Prof. Paulus Kirchhof, MD
Prof. Kirchhof shares the findings of the EAST-AF NET 4 trial, which evaluated the effect of early rhythm control in patients who were recently diagnosed with AF compared to usual care.

ESC 2020 Prof. Kirchhof shares the findings of the EAST-AF NET 4 trial, which evaluated the effect of early rhythm control in patients who were recently diagnosed with AF compared to usual care.

Family history of CHD and elevated Lp(a) have independent and additive joint associations with CV events

Literature - Sep. 15, 2020 - Mehta A et al., - J Am Coll Cardiol. 2020.

This study evaluated the independent and joint associations of elevated Lp(a) and family history of CHD with incident ASCVD and CHD events among asymptomatic subjects.

Increased risk of mortality and MACE in ACS patients with malnutrition

Literature - Sep. 15, 2020 - Raposeiras Roubín S, et al. - J Am Coll Cardiol 2020

Malnutrition, assessed by 3 different scores, was common in a cohort of ACS patients. Malnutrition was associated with increased risk of mortality and MACE, independent of BMI.

2018 Cholesterol guidelines do not identify half of young adults with premature MI

Literature - Sep. 15, 2020 - Zeitouni M et al. - J Am Coll Cardiol. 2020 Aug 11;76(6):653-664.

Half of young adults with premature MI are not identified as statin candidates before their event, and most are not recommended for intensive post-MI lipid management on basis of 2018 cholesterol guidelines.

LDL-c reduction with PCSK9 inhibitor in pediatric HeFH patients

News - Sep. 9, 2020

ESC 2020 Evolocumab, in addition to standard lipid-lowering therapies, resulted in a placebo-corrected difference of 38.3% for LDL-c after 24 weeks in pediatric HeFH patients.

Colchicine reduces CV death and ischemic events in chronic coronary disease

News - Sep. 9, 2020

ESC 2020 Colchicine reduced the risk of CV death, MI, ischemic stroke, or ischemia-driven coronary revascularization in patients with chronic coronary disease, compared to placebo.

Continuing versus suspending ACEi and ARBs in COVID-19

News - Sep. 9, 2020

ESC 2020 Suspension of ACEi/ARB therapy for 30 days did not impact the number of days alive and out of hospital at 30 days compared to continued use of these medications in COVID-19 patients.

Risk of major CV events reduced by BP lowering regardless of CVD status and baseline SBP

News - Sep. 9, 2020

ESC 2020 Blood pressure-lowering reduces the risk of major CV events similarly in those with and without CVD and irrespectively of baseline SBP.

Risk reduction for CV death or HF hospitalization with another SGLT2i in HFrEF

News - Sep. 9, 2020

ESC 2020 The EMPEROR-Reduced trial showed that empagliflozin reduced the risk of CV death or HF hospitalization by 25% in HFrEF patients with or without diabetes, compared to placebo.

In CKD, SGLT2i reduces risk of kidney failure, CV death or HF hospitalization, and all-cause mortality

News - Sep. 8, 2020

ESC 2020 The DAPA-CKD trial showed that dapagliflozin significantly reduced the risk of kidney failure, CV death or HF hospitalization, and all-cause mortality in patients with CKD, with and without T2DM, compared to placebo.